Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 13.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | in any such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain |
| 15.11.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 30.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
Stammdaten
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are used for the treatment of psoriasis, vitiligo, acne, and other skin conditions. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Unternehmen & Branche
| Name | STRATA Skin Sciences, Inc. |
|---|---|
| Ticker | SSKN |
| CIK | 0001051514 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 3841 · Surgical & Medical Instruments & Apparatus |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 697.531 USD |
| Beta | 0,34 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 30,696,000 | -6,261,000 | -1.35 | 30,521,000 | 2,908,000 |
| 2025-09-30 | 10-Q | 6,929,000 | -1,622,000 | -0.36 | 30,717,000 | 1,314,000 |
| 2025-06-30 | 10-Q | 7,663,000 | -2,575,000 | -0.62 | 29,493,000 | 532,000 |
| 2025-06-30 | 10-K | -2,575,000 | -0.62 | 29,493,000 | 532,000 | |
| 2025-03-31 | 10-K | -2,122,000 | -0.51 | 33,033,000 | 2,979,000 | |
| 2025-03-31 | 10-Q | 6,812,000 | -2,122,000 | -0.51 | 33,033,000 | 2,979,000 |
| 2024-12-31 | 10-K | 33,562,000 | -10,086,000 | -2.65 | 34,928,000 | 4,972,000 |
| 2024-09-30 | 10-Q | 8,797,000 | -2,074,000 | -0.51 | 39,383,000 | 9,401,000 |
| 2024-09-30 | 10-K | -2,074,000 | -0.51 | 39,383,000 | 9,401,000 | |
| 2024-06-30 | 10-Q | 8,435,000 | -91,000 | -0.03 | 38,759,000 | 9,506,000 |
| 2024-06-30 | 10-K | -91,000 | -0.03 | 38,759,000 | 9,506,000 | |
| 2024-03-31 | 10-K | -3,366,000 | -0.10 | 39,226,000 | 9,434,000 | |
| 2024-03-31 | 10-Q | 6,754,000 | -3,366,000 | -0.10 | 39,226,000 | 9,434,000 |
| 2023-12-31 | 10-K | 33,358,000 | -10,830,000 | -3.10 | 42,016,000 | 12,688,000 |
| 2023-09-30 | 10-Q | 8,852,000 | -1,053,000 | -0.30 | 47,193,000 | 16,193,000 |
| 2023-06-30 | 10-Q | 8,250,000 | -3,148,000 | -0.90 | 55,204,000 | 16,909,000 |
| 2023-03-31 | 10-Q | 7,567,000 | -2,835,000 | -0.08 | 49,123,000 | 19,321,000 |
| 2022-12-31 | 10-K | 36,161,000 | -5,549,000 | -0.16 | 52,272,000 | 21,831,000 |
| 2022-09-30 | 10-Q | 9,413,000 | -995,000 | -0.03 | 53,235,000 | 21,800,000 |
| 2022-06-30 | 10-Q | 9,105,000 | -1,892,000 | -0.05 | 53,587,000 | 22,340,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-11-18 | Rubinstein Samuel | Director | Open Market Purchase | 2,168 | 1.40 | 3,035.20 | +58,7% | |
| 2025-11-18 | Rubinstein Samuel | Director | Open Market Purchase | 2,832 | 1.41 | 3,993.12 | +77,3% | |
| 2025-11-17 | Rubinstein Samuel | Director | Open Market Sale | -1,394 | 1.36 | -1,895.84 | -36,7% | |
| 2025-11-17 | Rubinstein Samuel | Director | Open Market Sale | -5,500 | 1.32 | -7,260.00 | -140,5% | |
| 2025-11-17 | Rubinstein Samuel | Director | Open Market Sale | -7,200 | 1.34 | -9,648.00 | -186,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.